Pricing the Next Wave of COPD Therapies: Lessons from Current Reimbursement Patterns
Read More
June 2026
Pricing the Next Wave: Value, Competition, and Willingness-to-Pay in RRMS
Future therapies with strong clinical and economic value may still be able to achieve attractive pricing even in a competitive market.
In this Center for Pharmacoeconomics Spotlight, we estimate historical payer willingness-to-pay for oral and anti-CD20 disease-modifying therapies in relapsing-remitting multiple sclerosis. Rather than focusing on the list or net prices, we evaluate the total health system costs relative to the health outcomes achieved by these therapies. We then apply this framework to translate historical willingness-to-pay into value-anchored pricing for future RRMS therapies.
- Bottom Line: Payers have historically accepted high costs per health outcome gained in relapsing-remitting multiple sclerosis (RRMS). Future therapies with strong clinical and economic value may still be able to achieve attractive pricing even in a competitive market.
- While anti-CD20 therapies demonstrated superior efficacy, their annual net prices were generally lower than those of oral therapies during their respective exclusivity periods. This likely reflects the competitive commercial pressures faced by a new class of medications entering a market with existing or anticipated generic treatment options.
- Our analysis suggests that payers reimbursed these therapies at total health system costs of approximately $230,000 to $590,000 per quality-adjusted life year gained, with the more recently launched anti-CD20 class toward the lower end of this range. This may reflect increased payer leverage and tighter pricing expectations for newer entrants in a more competitive landscape, particularly in the presence of established therapies with anticipated generic alternatives.
- Building on these retrospective insights, we then applied our modeling framework to estimate value-anchored pricing for future entrants into the RRMS treatment landscape. Read the full report for our value-anchored price estimates for potential new RRMS therapies.
- These findings provide biotech executives and investors with a differentiated framework to assess value creation, competitive positioning, and potential pricing acceptance for development-stage RRMS therapies.
For details on obtaining full access to the report, contact us via email at cpe@medacorp.com.
The Leerink Center for Pharmacoeconomics is a division of MEDACorp and an affiliate of Leerink Partners
Leerink Center for Pharmacoeconomics
– Melanie Whittington, PhD, Managing Director, Head of the Center for Pharmacoeconomics
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
